|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||3.5300 - 3.5300|
|52 Week Range||2.9900 - 4.2400|
|Beta (5Y Monthly)||0.94|
|PE Ratio (TTM)||11.77|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Dec 20, 2019|
|1y Target Est||N/A|
Vensica Therapeutics ("Vensica"), a clinical stage biopharmaceutical company, announced that it has signed a strategic collaboration agreement with Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins Vensica has licensed Merz's botulinum neurotoxin A (Xeomin®) for needle-free use in urological procedures. Merz has acquired an equity position in Vensica.
AgroScout announced today that it has completed a Series A investment round of $7.5 million to expedite the development of its AI cloud platform for remote agronomy, and to increase its accessibility to the 500 million mostly unserved farms worldwide. The platform allows all growers – from the biggest to the smallest – to efficiently comply with the rising demand for sustainable crop protection and carbon accountability. The investment round was led by Kibbutz Yotvata. Other investors include Ag
Vessi Medical ("Vessi"), announced that it successfully completed a first-in-human case with its minimally invasive cryoablation solution for superficial bladder cancer (NMIBC). The procedure was performed at Rambam Healthcare Campus in Haifa, Israel.